Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: A double-blind, placebo-controlled study

Diabetes Care

Volumn 26, Issue 9, 2003, Pages 2588-2594

  Winkler, Karl ^b   Konrad, Thomas ^a   Füllert, Stefanie ^a   Friedrich, Isolde ^c   Destani, Ramadan ^c   Baumstark, Manfred W ^c   Krebs, Kristin ^c   Wieland, Heinrich ^c   März, Winfried ^c  

^a European RISC Study Center   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL;

ARTERIOSCLEROSIS; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PLACEBOS; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 0041322547     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.9.2588     Document Type: Article

References (46)

1. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H: Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 30:1144-1149, 1997
2. Osei K: Insulin resistance and systemic hypertension. Am J Cardiol 84:33J-36J, 1999
3. Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care 21:160-178, 1998
4. Reaven GM, Chen Y-DI, Jeppesen J, Maheux P, Krauss RM: Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 92:141-146, 1993
5. Austin MA, Edwards KL: Small, dense low density lipoprotein, and insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 7:167-171, 1996
6. Austin MA, King M-C, Vranizian KM, Krauss RM: Atherogenic lipoprotein phetype: a proposed genetic marker for coronary heart disease risk. Circulation 82:495-506, 1990
7. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921, 1988
8. Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PW, Schaefer EJ: Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb Vasc Biol 12:187-195, 1992
9. Coresh J, Kwiterovich Jr PO, Smith HH, Bachorik PS: Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 34:1687-1697, 1993
10. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J: Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 106:241-253, 1994
11. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276:875-881, 1996
12. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882-888, 1996
13. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 95:69-75, 1997
14. Gray RS, Robbins DC, Wang W, Yeh JL, Fabsitz RR, Cowan LD, Welty TK, Lee ET, Krauss RM, Howard BV: Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler Thromb Vasc Biol 17:2713-2720, 1997
15. Nigon F, Lesnik P, Rouis M, Chapman MJ: Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 32:1741-1753, 1991
16. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J: Influence of plasma lipid and LDL-subtraction profile on the interaction between low density lipoprotein with human arterial wall proleoglycans. Atherosclerosis 124:261-271, 1996
17. Vakkilainen J, Makimattila S, Seppala-Lindroos A, Vehkavaara S, Lahdenpera S, Groop PH, Taskinen MR, Yki-Jarvinen H: Endothelial dysfunction in men with small LDL particles. Circulation 102:716-721, 2000
18. Campos H, Roederer GO, Lussier-Cacan S, Davignon J, Krauss RM: Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease. Arterioscler Thromb Vasc Biol 15:1043-1048, 1995
19. Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM: Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA 286:1468-1474, 2001
20. Winkler K, Wetzka B, Hoffmann MM, Friedrich I, Kinner M, Baumstark MW, Zahradnik H-P, Wieland H, März W: Triglyceride-rich lipoproteins are associated with hypertension in preeclampsia. J Clin Endocrinol Metab 88:1162-1166, 2003
21. Fuchtenbusch M, Standl E, Schatz H: Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 108:151-163, 2000
22. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719, 2001
23. Yamasaki Y, Kawamori R, Wasada T, Sato A, Omori Y, Eguchi H, Tominaga M, Sasaki H, Ikeda M, Kubota M, Ishida Y, Hozumi T, Baba S, Uehara M, Shichiri M, Kaneko T: Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. Tohoku J Exp Med 183:173-183, 1997
24. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23:1605-1611, 2000
25. Eckland D, Danhof M: Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 108:S234-S242, 2000
26. King AB: A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones (Letter). Diabetes Care 23:557, 2000
27. Tack C, Demacker P, Smits P, Stalenhoef A: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 21:796-799, 1998
28. Winkler K, Friedrich I, Baumstark MW, Wieland H, März W: Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br J Diabetes Vase Dis 2:143-148, 2002
29. World Health Organization-International Society of Hypertension: Guidelines for the management of hypertension: guidelines subcommittee. J Hypertens 17:151-183, 1999
30. Füllert S, Schneider F, Haak E, Rau H, Badenhoop K, Lübben G, Usadel H-H, Konrad T: Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 87:5503-5506, 2002
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
32. Winkler K, Wetzka B, Hoffmann MM, Friedrich I, Kinner M, Baumstark MW, Wieland H, März W: Low density lipoprotein (LDL) subtractions during pregnancy: accumulation of buoyant LDL with advancing gestation. J Clin Endocrinol Metab 85:4543-4550, 2000
33. März W, Schamagl H, Abletshauser C, Hoffmann MM, Berg A, Keul J, Wieland H, Baumstark MW: Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 103:1942-1948, 2001
34. Baumstark MW, Kreutz W, Berg A, Frey I, Keul J: Structure of human low-density lipoprotein subfractions, determined by X-ray small-angle scattering. Biochim Biophy Acta 1037:48-57, 1990
35. Winkler K, Abletshauser C, Hoffmann MM, Friedrich I, Baumstark MW, Wieland H, März W: Effect of fluvastatin slow-release on low-density lipoprotein (LDL) subtractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 87:5485-5490, 2002
36. Schmitz G, Assmann G, Melnik B: The role of lecithin: cholesterol acyltransferase in high density lipoprotein3/high density lipoprotein2 interconversion. Clin Chim Acta 119:225-236, 1982
37. Tan KC, Shiu SW, Chu BY: Roles of hepatic lipase and cholesteryl ester transfer protein in determining low density lipoprotein subfraction distribution in Chinese patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 145:273-278, 1999
38. Austin MA, Mykkänen L, Kuusisto J, Edwards KL, Nelson C, Haffner SM, Pyörälä K, Laakso M: Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 92:1770-1778, 1995
39. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart J, Staels B: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96:741-750, 1995
40. Lehmann J, Moore L, Smith-Oliver T, Wilkinson W, Willson T, Kliewer S: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated rezeptor gamma (PPAR gamma) J Biol Chem 270:12953-12956, 1995
41. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadowaki T: A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ: effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 47:1841-1847, 1998
42. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H: Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278:704-711, 2000
43. Vu-Dac N, Schoonjans K, Laine B, Fruchart J, Auwerx J, Staels B: Negative regulation of the human apolipoprotein A-I promotor by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 269:31012-31018, 1994
44. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285:1585-1591, 2001
45. Watkins P, Whitcomb R: Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-917, 1998
46. Takeda Pharmaceuticals America: ACTOS Confronting the Challenges and Concerns of Type 2 Diabetes: A Product Monograph. Lincolnshire, IL, Takeda Pharmaceuticals, 1999